Joshua Mali, MD

Joshua Mali, MD, offers his prognostications for the new year

Over the past 2 years, retina specialists and their patients have learned how AI may be a tool physicians can use to monitor patients for disease progression, how telemedicine might mean more than a mere video chat between patient and clinician, and how the tools of the 21st century were closer to real-world practice than anticipated.

Joshua Mali, MD, shares how the FDA-approved faricimab-svoa (Vabysmo, Genentech) will change the treatment landscape for wet AMD and DME.

In light of another unprecedented year filled with technological advancements and pivots as a result of the pandemic, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2022.

In light of an unprecedented year filled with technological advancements and pivots, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2021.

Joshua Mali, MD, speaks on his annual top 5 predictions in ophthalmology for what's to come in 2021.

Financial takeovers rattle up the pharmaceutical world

In the first part of his Clinical Innovation series, Josh Mali, MD, shares how this novel home-use device is the new standard of care for AMD monitoring. Future blogs in the series will discuss the increased efficacy of patient monitoring and present case examples.

Josh Mali, MD, shares his predictions for the 2018 ophthalmic year.

Dr. Mali discusses how the Quarterly Questions program assesses fundamental (“walking around”) knowledge needed in the everyday practice of ophthalmology (40 questions annually), as well as the application of information from five journal articles (10 questions annually).

So far, 2017 has been a very exciting year for both ophthalmology and healthcare as a whole. We still have a few months left for more excitement, so stay tuned!

Joshua Mali, MD, provides clinical evidence and recommendations for pseudophakic CME and represents a new formal standard to first-line management.

As retinal specialists, we are truly fortunate to live in a time where we have several treatment options for patients with diabetic macular edema (DME). A fluocinolone acetonide (FAc) intravitreal implant 0.19 mg (Iluvien, Alimera Sciences) is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP.

As we sit down together with our families and friends for Thanksgiving dinner this year, we thought reflecting on the great innovations in the field of ophthalmology since the turn of this new century seemed timely (a topic that is a natural by-product of the marriage between a retinal surgeon and a pediatric ophthalmologist!).

In the medical field, it is very common to see long distance relationships amongst healthcare professionals including medical students, residents, and fellows who are often in different training programs across the country.

In his debut blog, Joshua Mali, MD, gives advice to his fellow residents on how to secure a stellar ophthalmic career.